|
 
- 现金
- 1748 元
- 精华
- 1
- 帖子
- 429
- 注册时间
- 2006-5-6
- 最后登录
- 2017-6-28
|
Hepatera is confident that Myrcludex B can be helpful in defeating chronic hepat
A biotechnology company "Hepatera" organized phase Ib-IIa clinical study of Myrcludex B in specialized clinical centers in Moscow, St. Petersburg, Chelyabinsk and Samara.
According to the PR office of the company, the developed drug is a synthesized peptide chain, similar in structure to a membrane protein of hepatitis B. Due to this structure it competitively binds to receptors on liver cells and blocks the virus. "Thus, the drug candidate provides for the recovery of the liver tissue and prevents further progression of the disease
and the development of complications such as cirrhosis and hepatocellular carcinoma".
"The Company intends to confirm the effectiveness of the drug against HBsAg clearance and its effect on the viral load, as well as demonstrate good tolerability and safety of the drug in the target population of patient".
It is expected that the results of the study, which was launched in Russia in the largest specialized centers, will be available by the end of 2013.
|
|
|
Don't waste precious energy on gossip, energy vampires, issues of the past, negative thoughts or things you cannot control. Instead invest your energy in the positive present moment.
别把宝贵的精力浪费在流言蜚语、白耗精力的事情、过去的问题、消极的想法或你不能控制的事情上，而是把精力放在积极的当下。
|
发表于 2013-5-20 19:11